Osteosarcoma Cell Line Cultivation and Manipulation

The human osteosarcoma cell lines, U2OS, SaOS2, and MG63 were purchased from the Korean Cell Line Bank (KCLB, Seoul, Korea). KHOS/NP cells were kindly provided by Chang-Bae Kong (Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Science) [27 (link)]. The cells were cultured in DMEM media containing 10% FBS (Gibco BRL, Gaithersburg, MD), and 10% penicillin/streptomycin (100 U/mL) at 37 °C in a humidified 5% CO₂ incubator. The PARP inhibitor, olaparib, was purchased from Santa Cruz Biotechnology (sc-302017, Santa Cruz Biotechnology, Santa Cruz, CA) and doxorubicin was obtained from Sigma (D1515, Sigma, St. Louis, MO). Short interfering RNA (siRNA) for PARP1 and negative control siRNA duplexes were purchased from Santa Cruz biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA). The cells were transfected using Lipofectamine® RNAiMax (Invitrogen, Life technologies, Carlsbad, CA).

Free full text: Click here

Park H.J., Bae J.S., Kim K.M., Moon Y.J., Park S.H., Ha S.H., Hussein U.K., Zhang Z., Park H.S., Park B.H., Moon W.S., Kim J.R, & Jang K.Y. (2018). The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. Journal of Experimental & Clinical Cancer Research : CR, 37, 107.

Publication 2018

SaOS2 FBS olaparib doxorubicin Lipofectamine® RNAiMax

Cell line Cells Cultured media Doxorubicin Human Korean Lipofectamine Olaparib Orthopedic surgery Osteosarcoma Parp inhibitor Parp1 Penicillin Radiological Short interfering rna Streptomycin

Corresponding Organization :

Other organizations : Chonbuk National University Hospital, Hongik University, Jeonbuk National University

Top 5 similar protocols

Variable analysis

independent variables

PARP inhibitor olaparib
Doxorubicin

dependent variables

Cell culture and growth

control variables

Cell culture media (DMEM with 10% FBS and 10% penicillin/streptomycin)
Incubation conditions (37 °C, 5% CO2)

controls

Negative control siRNA duplexes
Positive control: PARP1 siRNA

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!